Julie Jordan
Plus aucun poste en cours
Fortune : 11 748 $ au 30/04/2024
Profil
Julie Jordan is currently the Chief Medical Officer at Neurogene, Inc. She previously worked as the Executive Director-Clinical Development at Avanir Pharmaceuticals, Inc. and as the Senior Director-Clinical Development at Cerevel Therapeutics, Inc. From 2022 to 2023, she served as the Senior VP, Head-Clinical Development & Operations at Homology Medicines, Inc. Dr. Jordan also has a background in education, having obtained a doctorate degree from Harvard Medical School and an undergraduate degree from Harvard College.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
0,00% | 03/08/2023 | 416 ( 0,00% ) | 11 748 $ | 30/04/2024 |
Postes actifs de Julie Jordan
| Sociétés | Poste | Début |
|---|
Anciens postes connus de Julie Jordan
| Sociétés | Poste | Fin |
|---|---|---|
Cerevel Therapeutics, Inc.
 Cerevel Therapeutics, Inc. BiotechnologyHealth Technology Part of Cerevel Therapeutics Holdings, Inc., Cerevel Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company that develops therapies. The company is based in Cambridge, MA. The company was founded in 2018. N. Anthony Coles has been the CEO of the company since 2018. | Corporate Officer/Principal | - |
| AVANIR PHARMACEUTICALS INC | Corporate Officer/Principal | - |
| Q32 BIO INC. | Directeur des opérations | 09/03/2023 |
Formation de Julie Jordan
| Harvard College | Undergraduate Degree |
| Harvard Medical School | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 3 |
|---|---|
Homology Medicines, Inc.
 Homology Medicines, Inc. Pharmaceuticals: MajorHealth Technology Homology Medicines, Inc. is a clinical-stage genetic medicines company, which engages in the translation of proprietary gene editing and gene therapy technology into novel treatments for patients with rare genetic diseases. The company was founded in March 2015 and is headquartered in Bedford, MA. | Health Technology |
Cerevel Therapeutics, Inc.
Cerevel Therapeutics, Inc. BiotechnologyHealth Technology Part of Cerevel Therapeutics Holdings, Inc., Cerevel Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company that develops therapies. The company is based in Cambridge, MA. The company was founded in 2018. N. Anthony Coles has been the CEO of the company since 2018. | Health Technology |
Avanir Pharmaceuticals, Inc.
 Avanir Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Avanir Pharmaceuticals, Inc. engages in the development of therapeutic products for the treatment of nervous system disorder. The company was founded on August 31, 1988 and headquartered in Aliso Viejo, CA. | Health Technology |
